137 related articles for article (PubMed ID: 25448133)
1. Circulating miR-21, miR-146a and Fas ligand respond to postmenopausal estrogen-based hormone replacement therapy--a study with monozygotic twin pairs.
Kangas R; Pöllänen E; Rippo MR; Lanzarini C; Prattichizzo F; Niskala P; Jylhävä J; Sipilä S; Kaprio J; Procopio AD; Capri M; Franceschi C; Olivieri F; Kovanen V
Mech Ageing Dev; 2014 Dec; 143-144():1-8. PubMed ID: 25448133
[TBL] [Abstract][Full Text] [Related]
2. Declining Physical Performance Associates with Serum FasL, miR-21, and miR-146a in Aging Sprinters.
Kangas R; Törmäkangas T; Heinonen A; Alen M; Suominen H; Kovanen V; Laakkonen EK; Korhonen MT
Biomed Res Int; 2017; 2017():8468469. PubMed ID: 28127562
[TBL] [Abstract][Full Text] [Related]
3. Hormone replacement therapy enhances IGF-1 signaling in skeletal muscle by diminishing miR-182 and miR-223 expressions: a study on postmenopausal monozygotic twin pairs.
Olivieri F; Ahtiainen M; Lazzarini R; Pöllänen E; Capri M; Lorenzi M; Fulgenzi G; Albertini MC; Salvioli S; Alen MJ; Kujala UM; Borghetti G; Babini L; Kaprio J; Sipilä S; Franceschi C; Kovanen V; Procopio AD
Aging Cell; 2014 Oct; 13(5):850-61. PubMed ID: 25040542
[TBL] [Abstract][Full Text] [Related]
4. Muscle function in monozygotic female twin pairs discordant for hormone replacement therapy.
Finni T; Noorkoiv M; Pöllänen E; Ronkainen PH; Alén M; Kaprio J; Kovanen V; Sipilä S
Muscle Nerve; 2011 Nov; 44(5):769-75. PubMed ID: 22006692
[TBL] [Abstract][Full Text] [Related]
5. Global gene expression profiles in skeletal muscle of monozygotic female twins discordant for hormone replacement therapy.
Ronkainen PH; Pöllänen E; Alén M; Pitkänen R; Puolakka J; Kujala UM; Kaprio J; Sipilä S; Kovanen V
Aging Cell; 2010 Dec; 9(6):1098-110. PubMed ID: 20883525
[TBL] [Abstract][Full Text] [Related]
6. Aging and serum exomiR content in women-effects of estrogenic hormone replacement therapy.
Kangas R; Törmäkangas T; Fey V; Pursiheimo J; Miinalainen I; Alen M; Kaprio J; Sipilä S; Säämänen AM; Kovanen V; Laakkonen EK
Sci Rep; 2017 Feb; 7():42702. PubMed ID: 28195143
[TBL] [Abstract][Full Text] [Related]
7. Age and estrogen-based hormone therapy affect systemic and local IL-6 and IGF-1 pathways in women.
Ahtiainen M; Pöllänen E; Ronkainen PH; Alen M; Puolakka J; Kaprio J; Sipilä S; Kovanen V
Age (Dordr); 2012 Oct; 34(5):1249-60. PubMed ID: 21845403
[TBL] [Abstract][Full Text] [Related]
8. MitomiRs in human inflamm-aging: a hypothesis involving miR-181a, miR-34a and miR-146a.
Rippo MR; Olivieri F; Monsurrò V; Prattichizzo F; Albertini MC; Procopio AD
Exp Gerontol; 2014 Aug; 56():154-63. PubMed ID: 24607549
[TBL] [Abstract][Full Text] [Related]
9. Hormone therapy is associated with better body composition and adipokine/glucose profiles: a study with monozygotic co-twin control design.
Ahtiainen M; Alen M; Pöllänen E; Pulkkinen S; Ronkainen PH; Kujala UM; Kaprio J; Sipilä S; Kovanen V
Menopause; 2012 Dec; 19(12):1329-35. PubMed ID: 22914204
[TBL] [Abstract][Full Text] [Related]
10. Postmenopausal hormone replacement therapy modifies skeletal muscle composition and function: a study with monozygotic twin pairs.
Ronkainen PH; Kovanen V; Alén M; Pöllänen E; Palonen EM; Ankarberg-Lindgren C; Hämäläinen E; Turpeinen U; Kujala UM; Puolakka J; Kaprio J; Sipilä S
J Appl Physiol (1985); 2009 Jul; 107(1):25-33. PubMed ID: 19246654
[TBL] [Abstract][Full Text] [Related]
11. Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women.
Christodoulakos GE; Lambrinoudaki IV; Creatsa MG; Economou EV; Siasou Z; Panoulis CP; Kalligerou I; Papadias C
Climacteric; 2008 Apr; 11(2):155-65. PubMed ID: 18365858
[TBL] [Abstract][Full Text] [Related]
12. ESR1 and APOE gene polymorphisms, serum lipids, and hormonal replacement therapy.
Almeida S; Fiegenbaum M; de Andrade FM; Osório-Wender MC; Hutz MH
Maturitas; 2006 May; 54(2):119-26. PubMed ID: 16242874
[TBL] [Abstract][Full Text] [Related]
13. OGT and OGA expression in postmenopausal skeletal muscle associates with hormone replacement therapy and muscle cross-sectional area.
Toivonen MH; Pöllänen E; Ahtiainen M; Suominen H; Taaffe DR; Cheng S; Takala T; Kujala UM; Tammi MI; Sipilä S; Kovanen V
Exp Gerontol; 2013 Dec; 48(12):1501-4. PubMed ID: 24365779
[TBL] [Abstract][Full Text] [Related]
14. Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy.
de Maat MP; Madsen JS; Langdahl B; Bladbjerg EM; Tofteng CL; Abrahamsen B; Rejnmark L; Brixen K; Christensen K; Jespersen J; Kristensen SR
Thromb Haemost; 2007 Feb; 97(2):234-9. PubMed ID: 17264952
[TBL] [Abstract][Full Text] [Related]
15. Effects of hormone replacement therapy on plasma pro-inflammatory and anti-inflammatory cytokines and some bone turnover markers in postmenopausal women.
Vural P; Akgul C; Canbaz M
Pharmacol Res; 2006 Oct; 54(4):298-302. PubMed ID: 16879975
[TBL] [Abstract][Full Text] [Related]
16. Leukocyte and Skeletal Muscle Telomere Length and Body Composition in Monozygotic Twin Pairs Discordant for Long-term Hormone Replacement Therapy.
Sillanpää E; Niskala P; Laakkonen EK; Ponsot E; Alén M; Kaprio J; Kadi F; Kovanen V; Sipilä S
Twin Res Hum Genet; 2017 Apr; 20(2):119-131. PubMed ID: 28193312
[TBL] [Abstract][Full Text] [Related]
17. Effects of sex and postmenopausal estrogen use on serum phosphorus levels: a cross-sectional study of the National Health and Nutrition Examination Survey (NHANES) 2003-2006.
Zhang D; Maalouf NM; Adams-Huet B; Moe OW; Sakhaee K
Am J Kidney Dis; 2014 Feb; 63(2):198-205. PubMed ID: 24051078
[TBL] [Abstract][Full Text] [Related]
18. Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study.
Khosla S; Atkinson EJ; Melton LJ; Riggs BL
J Clin Endocrinol Metab; 1997 May; 82(5):1522-7. PubMed ID: 9141544
[TBL] [Abstract][Full Text] [Related]
19. Basal leg blood flow in healthy women is related to age and hormone replacement therapy status.
Moreau KL; Donato AJ; Tanaka H; Jones PP; Gates PE; Seals DR
J Physiol; 2003 Feb; 547(Pt 1):309-16. PubMed ID: 12562958
[TBL] [Abstract][Full Text] [Related]
20. Influence of current and past hormone replacement therapy on bone mineral density: a study of discordant postmenopausal twins.
George GH; MacGregor AJ; Spector TD
Osteoporos Int; 1999; 9(2):158-62. PubMed ID: 10367044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
